|
1
|
Louis DN: Molecular pathology of malignant
gliomas. Annu Rev Pathol. 1:97–117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maher EA, Furnari FB, Bachoo RM, Rowitch
DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics
and biology of a grave matter. Genes Dev. 15:1311–1333. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang
X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice
guidelines for the management of adult diffuse gliomas. Cancer
Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang W, Zhang J, Hoadley K, Kushwaha D,
Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, et al:
miR-181d: A predictive glioblastoma biomarker that downregulates
MGMT expression. Neuro Oncol. 14:712–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K,
Ye WL, Hu BQ, Yan W, Zhang W, Akers J, et al: RNA-seq of 272
gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in
secondary glioblastomas. Genome Res. 24:1765–1773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayden MS and Ghosh S: NF-κB, the first
quarter-century: Remarkable progress and outstanding questions.
Genes Dev. 26:203–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baud V and Collares D: Post-translational
modifications of RelB NF-κB subunit and associated functions.
Cells. 5(pii): E222016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhat KPL, Balasubramaniyan V, Vaillant B,
Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L,
James JD, Goodman LD, et al: Mesenchymal differentiation mediated
by NF-κB promotes radiation resistance in glioblastoma. Cancer
Cell. 24:331–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raychaudhuri B, Han Y, Lu T and Vogelbaum
MA: Aberrant constitutive activation of nuclear factor kappaB in
glioblastoma multiforme drives invasive phenotype. J Neurooncol.
85:39–47. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lopez-Guerra M and Colomer D: NF-kappaB as
a therapeutic target in chronic lymphocytic leukemia. Expert Opin
Ther Targets. 14:275–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun SC: Non-canonical NF-κB signaling
pathway. Cell Res. 21:71–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Belguise K, Kersual N, Kirsch KH,
Mineva ND, Galtier F, Chalbos D and Sonenshein GE: Oestrogen
signalling inhibits invasive phenotype by repressing RelB and its
target BCL2. Nat Cell Biol. 9:470–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu H, Wang Z, Liu Y, Zhang C, Li M, Zhang
W, Wang K, Cai J, Cheng W, Huang H and Jiang T: Genome-wide
transcriptional analyses of Chinese patients reveal cell migration
is attenuated in IDH1-mutant glioblastomas. Cancer Lett.
357:566–574. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun Y, Zhang W, Chen D, Lv Y, Zheng J,
Lilljebjörn H, Ran L, Bao Z, Soneson C, Sjögren HO, et al: A glioma
classification scheme based on coexpression modules of EGFR and
PDGFRA. Proc Natl Acad Sci USA. 111:3538–3543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li
G, Liang J, Hu H, Liu Y, Zhang W and Jiang T: Molecular and
clinical characterization of PD-L1 expression at transcriptional
level via 976 samples of brain glioma. Oncoimmunology.
5:e11963102016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu Z, Gu L, Eils R, Schlesner M and Brors
B: Circlize implements and enhances circular visualization in R.
Bioinformatics. 30:2811–2812. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang ZL, Zhao LJ, Chai L, Zhou SH, Wang
F, Wei Y, Xu YP and Zhao P: Seven LncRNA-mRNA based risk score
predicts the survival of head and neck squamous cell carcinoma. Sci
Rep. 7:3092017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JY and Nam JH: Progestins in the
fertility-sparing treatment and retreatment of patients with
primary and recurrent endometrial cancer. Oncologist. 20:270–278.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burkly L, Hession C, Ogata L, Reilly C,
Marconi LA, Olson D, Tizard R, Cate R and Lo D: Expression of relB
is required for the development of thymic medulla and dendritic
cells. Nature. 373:531–536. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baud V and Jacque E: The alternative NF-kB
activation pathway and cancer: Friend or foe? Med Sci (Paris).
24:1083–1088. 2008.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mineva ND, Wang X, Yang S, Ying H, Xiao
ZX, Holick MF and Sonenshein GE: Inhibition of RelB by
1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer
cells to radiation. J Cell Physiol. 220:593–599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Demicco EG, Kavanagh KT, Romieu-Mourez R,
Wang X, Shin SR, Landesman-Bollag E, Seldin DC and Sonenshein GE:
RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland
development in transgenic mice with targeted superrepressor
IkappaB-alpha expression and promote carcinogenesis of the mammary
gland. Mol Cell Biol. 25:10136–10147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu Y, Josson S, Fang F, Oberley TD, St
Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A and St
Clair WH: RelB enhances prostate cancer growth: Implications for
the role of the nuclear factor-kappaB alternative pathway in
tumorigenicity. Cancer Res. 69:3267–3271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Josson S, Xu Y, Fang F, Dhar SK, St Clair
DK and St Clair WH: RelB regulates manganese superoxide dismutase
gene and resistance to ionizing radiation of prostate cancer cells.
Oncogene. 25:1554–1559. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee DW, Ramakrishnan D, Valenta J, Parney
IF, Bayless KJ and Sitcheran R: The NF-κB RelB protein is an
oncogenic driver of mesenchymal glioma. PLoS One. 8:e574892013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cherry EM, Lee DW, Jung JU and Sitcheran
R: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
promotes glioma cell invasion through induction of NF-κB-inducing
kinase (NIK) and noncanonical NF-κB signaling. Mol Cancer.
14:92015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cormier F, Monjanel H, Fabre C, Billot K,
Sapharikas E, Chereau F, Bordereaux D, Molina TJ, Avet-Loiseau H
and Baud V: Frequent engagement of RelB activation is critical for
cell survival in multiple myeloma. PLoS One. 8:e591272013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ge QL, Liu SH, Ai ZH, Tao MF, Ma L, Wen
SY, Dai M, Liu F, Liu HS, Jiang RZ, et al: RelB/NF-κB links cell
cycle transition and apoptosis to endometrioid adenocarcinoma
tumorigenesis. Cell Death Dis. 7:e24022016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vallabhapurapu S and Karin M: Regulation
and function of NF-kappaB transcription factors in the immune
system. Annu Rev Immunol. 27:693–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baldwin AS: Regulation of cell death and
autophagy by IKK and NF-κB: Critical mechanisms in immune function
and cancer. Immunol Rev. 246:327–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vogel CF, Wu D, Goth SR, Baek J, Lollies
A, Domhardt R, Grindel A and Pessah IN: Aryl hydrocarbon receptor
signaling regulates NF-κB RelB activation during dendritic-cell
differentiation. Immunol Cell Biol. 91:568–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu HC, Qiu T, Liu XH, Dong WC, Weng XD,
Hu CH, Kuang YL, Gao RH, Dan C and Tao T: Tolerogenic dendritic
cells generated by RelB silencing using shRNA prevent acute
rejection. Cell Immunol. 274:12–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu L, Bai Y and Wang Z: Elevated T cell
activation score is associated with improved survival of breast
cancer. Breast Cancer Res Treat. 164:689–696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun C, Sang M, Li S, Sun X, Yang C, Xi Y,
Wang L, Zhang F, Bi Y, Fu Y and Li D: Hsa-miR-139-5p inhibits
proliferation and causes apoptosis associated with down-regulation
of c-Met. Oncotarget. 6:39756–39792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM,
Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses
metastasis and progression of hepatocellular carcinoma by
down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang K, Jin J, Ma T and Zhai H: miR-139-5p
inhibits the tumorigenesis and progression of oral squamous
carcinoma cells by targeting HOXA9. J Cell Mol Med. 21:3730–3740.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu X, Duan B, Dong Y, He C, Zhou H, Sheng
H, Gao H and Zhang X: MicroRNA-139-3p indicates a poor prognosis of
colon cancer. Int J Clin Exp Pathol. 7:8046–8052. 2014.PubMed/NCBI
|
|
46
|
Wang M, Wen TF, He LH, Li C, Zhu WJ and
Trishul NM: A six-microRNA set as prognostic indicators for bile
duct cancer. Int J Clin Exp Med. 8:17261–17270. 2015.PubMed/NCBI
|
|
47
|
Huang P, Xi J and Liu S: miR-139-3p
induces cell apoptosis and inhibits metastasis of cervical cancer
by targeting NOB1. Biomed Pharmacother. 83:850–856. 2016.
View Article : Google Scholar : PubMed/NCBI
|
